PDCD1 and cancer: Their study indicated that administration of a PD-1 inhibitor increased the rate of infiltration of immune cells into tumors and resulted in significantly lower levels of GLUT1high /hexokinase-IIhigh cells in CD45− cancer cells, suggesting that the change in glucose uptake activity is associated with a difference in levels of infiltration or activation of immune cells.